PMID: 8938222Jan 1, 1996Paper

Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy

Acta Oncologica
R BlomE Simonsen

Abstract

This retrospective study evaluates paclitaxel (Taxol) monotherapy in the treatment of advanced ovarian cancer, previously treated with cisplatin. Forty-six patients with FIGO stage IC to IV were given Taxol in doses of 175 mg/m2 and 135 mg/m2 as a 3-h continuous infusion. All patients were given premedication (prednisone, clemastin, cimetidine) to prevent hypersensitivity reactions. One allergic reaction was observed. Thirty-nine patients showed progress of their disease during treatment and seven showed a response (overall response rate 15.2%; 95% c.i. 4.8-25.6%). There were five total (10.9%) and two partial responses. Among 20 patients who had progressed during or within 6 months of prior cisplatin-based therapy two were responders and two showed partial response (10%). Among 26 patients who had responded to cisplatin but suffered recurrence more than 6 months after cisplatin treatment, there were five total responders (19.2%). We conclude that Taxol treatment does not alter the fact that advanced ovarian carcinoma still carries a grave prognosis. Taxol monotherapy treatment of patients not responding to first line platinum treatment or having relapse within six months of completed therapy, seems to have a limited effect. Fo...Continue Reading

References

Feb 22, 1979·Nature·P B SchiffS B Horwitz
Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A I EinzigG L Goldberg
Aug 1, 1990·Journal of the National Cancer Institute·E K RowinskyR C Donehower
Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Aug 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtJ B Vermorken
Jan 5, 1994·Journal of the National Cancer Institute·E C KohnF P Ognibene
Feb 1, 1995·Annals of Medicine·R F Ozols
Jun 1, 1994·American Journal of Obstetrics and Gynecology·V L SeewaldtS A Miller
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A Cannistra
Sep 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J T ThigpenR J Barrett
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A EisenhauerN Colombo
Jan 1, 1993·Cancer Treatment Reviews·R C Donehower, E K Rowinsky

❮ Previous
Next ❯

Citations

Feb 7, 2001·Cancer Investigation·D KhayatD Coeffic
Nov 25, 2003·Cancer Investigation·David M BorutaLinda Van Le

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
G AravantinosG Fountzilas
© 2021 Meta ULC. All rights reserved